Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers

Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers
The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer, who respond to platinum-based chemotherapy. This decision follows a positive recommendation issued by the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA). Zejula is now the first PARP inhibitor to be approved in Europe as a stand-alone therapy for women with advanced ovarian cancer, regardless of whether their tumors are defective in DNA repair genes. “Over 65,000 women in Europe are diagnosed with ovarian cancer each year. This approval of Zejula means that many more women will have the option to receive this innovative medicine earlier, potentially extending the time they may spend without their devastating cancer progressing,” Hal Barron, chief scientific officer and president of Research and Development at GlaxoSmithKline (GSK), said in a
Subscribe or to access all post and page content.